Microbot Medical Inc. (MBOT)
| Market Cap | 74.55M -22.8% |
| Revenue (ttm) | 346,000 |
| Net Income | -16.34M |
| EPS | -0.26 |
| Shares Out | 67.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 817,268 |
| Open | 1.100 |
| Previous Close | 1.070 |
| Day's Range | 1.050 - 1.120 |
| 52-Week Range | 0.930 - 2.855 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 5.38 (+384.23%) |
| Est. Earnings | Nov 20, 2026 |
About MBOT
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal rev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MBOT stock is "Strong Buy." The 12-month stock price target is $5.38, which is an increase of 384.23% from the latest price.
News
Microbot Medical granted patent by CIPO
Microbot Medical (MBOT) announced that the Canadian Intellectual Property Office, or CIPO, granted the company a patent for an adaptor for coupling a proximal portion of an elongate surgical tool…
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
HINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that the Canad...
Microbot Medical Proxy statement: Proxy filing
Microbot Medical filed a proxy statement on November 3, 2026, providing details for shareholder voting and corporate governance matters.
Microbot Medical Proxy statement: Proxy filing
Microbot Medical filed a proxy statement on November 3, 2026, providing details for shareholder voting and corporate governance matters.
Microbot Medical secures first OBL customer for Liberty devices
Microbot Medical (MBOT) announced that ELMNT IR, a multisite outpatient interventional radiology practice in California, has signed an order to purchase up to a 12-month supply of Liberty devices. ELM...
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company's Full Market Release strategy. The Company believes the OBLs represent a rapidl...
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that key execu...
Microbot Medical initiated with an Outperform at Citizens
Citizens initiated coverage of Microbot Medical (MBOT) with an Outperform rating and $2.50 price target The company is entering the early stages of commercialization with Liberty, the first single-use...
Microbot Medical receives several new Liberty System patent approvals globally
Microbot Medical (MBOT) announced that it has received several new patent approvals across the U.S., Japan, China and Canada, further strengthening its global intellectual property portfolio as the co...
Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.
Microbot Medical signs exclusive commercial distribution pact with Medtechnica
Microbot Medical (MBOT) announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica to market and sell the company’s Liberty System in Israel. The company re...
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Ma...
Microbot Medical® Highlights Growth Strategy
Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
Microbot Medical price target lowered to $3 from $4 at Lucid Capital
Lucid Capital analyst Alex Nowak lowered the firm’s price target on Microbot Medical (MBOT) to $3 from $4 and keeps a Buy rating on the shares following the analyst event.
Microbot Medical transferred with Buy rating at B. Riley
B. Riley analyst William Wood kept a Buy rating on Microbot Medical (MBOT) with a $4 price target following a transfer of coverage. The company commercializes Liberty, the first and…
Microbot Medical price target lowered to $4 from $5 at B. Riley
B. Riley lowered the firm’s price target on Microbot Medical (MBOT) to $4 from $5 and keeps a Buy rating on the shares. Microbot Medical’s Q2 revenue missed expectations as…
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Re...
Microbot Medical Quarterly report: Q2 2026
Microbot Medical has published its Q2 2026 quarterly earnings report on August 11, 2026.
Microbot Medical Earnings release: Q2 2026
Microbot Medical released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this ...
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health ...
Microbot Medical increases manufacturing capacity for Liberty System
Microbot Medical (MBOT) has entered into a letter of agreement with Sanmina Corporation to manufacture the Liberty System. The company believes it is necessary to expand its manufacturing capacity to…
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of A...
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the ...
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Leading academic center with multi-hospital and multi-state health system deepens Company's footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LI...